Compounds > 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol
Page last updated: 2024-09-03

4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol and Drug Withdrawal Symptoms

4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol has been researched along with Drug Withdrawal Symptoms in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chang, WH; Chen, LC; Chien, CP; Hu, WH; Jann, MW; Juang, DJ; Lam, YW; Lin, SK; Yang, CH1

Other Studies

1 other study(ies) available for 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol and Drug Withdrawal Symptoms

ArticleYear
Prolonged haloperidol and reduced haloperidol plasma concentrations after decanoate withdrawal.
    Schizophrenia research, 1993, Volume: 9, Issue:1

    Topics: Adult; Female; Half-Life; Haloperidol; Humans; Injections, Intramuscular; Male; Metabolic Clearance Rate; Middle Aged; Schizophrenia; Schizophrenic Psychology; Substance Withdrawal Syndrome

1993